
Cohere
Cohere licenses its Command, Embed, Rerank, Parse and Transcribe models and its North and Compass applications through a pay-as-you-go API, single-tenant Model Vault instances, hyperscaler marketplaces and private deployments, each governed by a different agreement.
Start Here
Guides
Licensing Data
From the Cohere catalog: how usage is counted, the rules that apply, the programs licences are bought through and the SKUs. Backed by 90 verbatim excerpts from 31 Cohere documents.
Metrics 13
View All 13Rules 90
View All 90Programs 16
View All 16SKUs 21
View All 21Products
All 12 ProductsGenerative AI Software 6
Cohere API, Cohere Aya, Cohere Command, Cohere Command A, Cohere Command R, Cohere North
Machine Learning Software 4
Cohere Embed, Cohere Model Vault, Cohere Parse, Cohere Rerank
Enterprise Search Software 1
Cohere Compass
Transcription Software 1
Cohere Transcribe
Product History
All acquisitions- Cohere acquired Reliant AI
Cohere announced that it had acquired Reliant AI, a biopharma AI company with operations in Montreal and Berlin, to expand its sovereign enterprise AI offering in healthcare and life sciences.
Legacy product Became Reliant AI research workbench Merged into North for Pharma · Cohere said Reliant's technology would be integrated to build North for Pharma Licensing impactSources and full product history- Cohere said it would bring Reliant AI's research team, proprietary biomedical datasets and domain-optimised technology into its sovereign AI platform and accelerate North for Pharma, an agentic system for biopharma teams.[1]
- Reliant AI's CEO Karl Moritz Hermann joins Cohere as VP of AI Verticalizations and co-founder Marc Bellemare as VP of Modelling.[1]
Litigation
All cases- Lessons learned
- A court let claims proceed that a model's retrieval-augmented outputs, not only its training, can reproduce or closely paraphrase protected articles.
- Marketing a model for a use, such as summarising the latest news, was treated at the pleading stage as possible evidence of inducement.
- Investigator-obtained outputs were accepted at the pleading stage as evidence of typical third-party use, despite a terms-of-service objection.